Stock listing

NASDAQ:SEPN Septerna, Inc. Stock

Home listing (NASDAQ) of Septerna, Inc.

Follow Septerna, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:SEPN

$38.61 USD -0.84 (-2.1%)

Close on Nov 20, 2026

Past year +62.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$38.23 – $39.89 USDNov 20, 2026
Volume
374,248 sharesNov 20, 2026
Market cap
$1.84B USDAt the close on Nov 20, 2026 · price × 47.55M shares outstanding
52-week range
$22.78 – $53.34 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$15.70M USDMedian day 344,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Septerna, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:SEPN · Home$38.61 USD-0.84 (-2.1%)374,248$38.72$39.89$38.23$39.45Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SEPN · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$38.61-0.84-2.1%$38.72$39.89$38.23374,248
$39.45-0.57-1.4%$39.85$41.52$39.05298,919
$40.02-1.65-4.0%$41.67$41.67$39.28271,754
$41.67-0.93-2.2%$42.86$42.95$40.83385,334
$42.60+0.74+1.8%$41.66$42.88$40.60337,791
$41.86-6.70-13.8%$47.89$47.97$41.65607,531
$48.56-3.78-7.2%$51.90$53.34$45.261,127,403
$52.34+1.60+3.2%$49.35$52.54$46.84537,115
$50.74+1.89+3.9%$49.86$50.82$48.07713,674
$48.85+1.50+3.2%$48.20$51.05$47.84384,548
$47.35-0.53-1.1%$47.90$48.08$45.96533,933
$47.88+4.18+9.6%$45.60$48.23$44.79604,656
$43.70+0.50+1.2%$43.53$44.58$42.22307,509
$43.20-0.80-1.8%$44.06$44.95$41.07475,332
$44.00-1.23-2.7%$45.00$45.43$43.68223,449
$45.23+0.98+2.2%$44.43$45.60$43.74200,615
$44.25+0.11+0.2%$43.51$45.08$41.92380,134
$44.14+2.76+6.7%$41.78$44.22$40.97261,813
$41.38+0.97+2.4%$40.42$41.95$38.39279,428
$40.41-0.47-1.1%$40.63$41.21$39.65200,300
$40.88+0.12+0.3%$40.72$41.77$39.70251,100
$40.76+1.41+3.6%$39.57$41.40$38.75286,400
$39.35+2.97+8.2%$36.46$39.55$36.25418,300
$36.38+0.03+0.1%$36.48$37.82$36.04410,200
$36.35-1.10-2.9%$37.47$37.47$35.09234,100
$37.45+1.13+3.1%$36.78$38.36$36.22271,400
$36.32-0.095-0.3%$36.00$37.28$34.36370,000
$36.42-1.145-3.0%$37.49$38.51$36.28491,900
$37.56-0.81-2.1%$38.32$38.41$37.25207,600
$38.37+1.47+4.0%$36.76$38.73$35.77349,400
$36.90+0.90+2.5%$35.47$37.09$34.66745,400
$36.00+0.33+0.9%$35.27$37.14$35.201,028,400
$35.67-2.20-5.8%$37.97$38.69$35.60490,400
$37.87+0.16+0.4%$37.83$38.52$36.82266,700
$37.71-0.34-0.9%$38.84$39.11$37.31395,400
$38.05-1.08-2.8%$38.90$39.52$37.81545,100
$39.130.000.0%$39.13$39.85$38.49209,600
$39.13-0.61-1.5%$39.52$39.57$38.37564,500
$39.74+1.97+5.2%$37.61$39.78$37.03338,300
$37.77-0.36-0.9%$38.34$38.34$37.35344,300
$38.13-0.32-0.8%$38.41$38.81$37.49293,000
$38.45-1.93-4.8%$40.17$40.17$36.98509,700
$40.38+1.84+4.8%$38.78$41.09$38.74412,000
$38.54-0.15-0.4%$38.97$39.47$38.01252,400
$38.69-0.81-2.1%$39.28$39.48$37.88448,200
$39.50+1.06+2.8%$39.38$40.52$39.01256,800
$38.44-0.42-1.1%$39.15$40.24$37.92304,900
$38.86-0.69-1.7%$39.52$39.52$38.26269,600
$39.55+1.04+2.7%$38.66$39.95$38.51356,000
$38.51+0.76+2.0%$37.75$40.02$37.56354,300
$37.75-0.22-0.6%$37.37$38.43$36.60338,700
$37.97+0.60+1.6%$37.15$39.40$37.15475,300
$37.37+0.62+1.7%$36.15$38.06$36.01309,900
$36.75-0.05-0.1%$36.57$37.59$36.57199,700
$36.80-0.70-1.9%$37.72$38.20$36.46241,500
$37.50-0.18-0.5%$37.96$38.86$37.25263,200
$37.68-0.47-1.2%$38.15$38.57$37.24264,000
$38.15-0.76-2.0%$38.71$39.11$37.39415,300
$38.91-1.56-3.9%$40.25$40.95$38.74385,900
$40.47+0.22+0.5%$40.01$41.08$39.95266,500
$40.25-1.05-2.5%$41.08$41.36$40.12168,500
$41.30+0.78+1.9%$41.57$41.85$40.47333,400
$40.52+0.52+1.3%$39.76$40.90$38.96520,500
$40.00-0.79-1.9%$41.44$41.44$39.95289,800
$40.79-3.14-7.1%$43.15$43.62$40.24429,900
Ticker
NASDAQ:SEPN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Septerna, Inc. news

Septerna, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
18 in the last 12 months · 32 in all · newest Nov 9, 2026 · oldest 2024
Decks
9 decks · latest Nov 4, 2026

Where Septerna, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:SEPN · Home listing · This pageNASDAQUnited StatesUSD
BOATS:SEPNBOATSUnited StatesUSD

Valuation

EV/sales 14.3× against a median of 5.0×: 4th lowest of 5 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$1.38B USD
P/E
Loss
EV/sales
14.3×
EV/EBITDA
Negative EBITDA
Price/book
4.3×
Gross margin
Not reported
Operating margin
−76.2%
Net margin
−61.3%
Debt to equity
0.1×
Beta vs S&P 500
0.95

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Septerna, Inc. · NASDAQ:SEPNUS$1.84BUS$1.38Bn/a14.3×n/a4.3×−61.3%0.1×0.95
Shanghai Henlius Biotech, Inc. Class H · HKEX:2696US$1.91BUS$2.36B14.7×2.1×12.3×2.8×11.7%0.9×n/a
Trevi Therapeutics, Inc. · NASDAQ:TRVIUS$1.90BUS$1.60Bn/an/an/a6.3×n/a0.0×1.22
Biohaven Ltd. · NYSE:BHVNUS$1.87BUS$1.71Bn/an/an/an/an/an/a1.19
BioCryst Pharmaceuticals, Inc. · NASDAQ:BCRXUS$1.86BUS$1.88Bn/a1.9×n/an/a−37.4%n/a0.62
Immunome, Inc. · NASDAQ:IMNMUS$1.85BUS$1.40Bn/an/an/a4.1×n/a0.0×1.49
Zymeworks Inc. · NASDAQ:ZYMEUS$1.84BUS$2.08B42.5×7.8×40.6×7.1×16.3%1.3×0.69
Vera Therapeutics, Inc. · NASDAQ:VERAUS$1.84BUS$1.53Bn/a149×n/a5.5×n/a0.2×1.13
Hemab Therapeutics Holdings, Inc. · NASDAQ:COAGUS$1.84BUS$1.41Bn/an/an/a4.3×n/a0.0×0.61
Braveheart Bio, Inc. · NASDAQ:BRVEUS$1.84BUS$1.71Bn/an/an/a3.7×n/a0.0×n/a
Replimune Group, Inc. · NASDAQ:REPLUS$1.81BUS$1.60Bn/an/an/a8.8×n/a0.5×0.78
Median of the othersUS$1.85BUS$1.66B28.6×5.0×26.5×4.9×11.7%0.1×0.96

Forecasts

9 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
59.22 USD · Analysts' mean
EPS, year to Dec 2026
-1.20 · 3 analysts
Revenue, year to Dec 2026
94.38M · 10 analysts

Team and board

Officers

OfficerRole
Jeffrey FinerChief Executive Officer and Co-Founder
Gil LabrucherieChief Financial Officer
Liz BhattPresident and Chief Operating Officer
Mark A. WilsonChief Legal Officer
Daniel LongSenior Vice President, Drug Discovery
Uwe KleinSenior Vice President, Biological Sciences
Rajiv PatniChief Medical Officer
Samira ShaikhlyChief People Officer

Board

DirectorRole
Jeffrey TongChairman of the Board
Abraham BassanDirector
Alan EzekowitzDirector
Bernard CoulieDirector
Jake SimsonDirector
Jeffrey FinerChief Executive Officer and Co-Founder
Keith M. GottesdienerDirector
Shalini SharpDirector

Events

QuarterResultsShare move
Q3 2026Nov 9, 2026 · After close+3.1%
Q2 2026Aug 10, 2026 · After close+22.9%
Q1 2026May 11, 2026 · After close+5.4%
Q4 2025Mar 26, 2026−1.4%
Q3 2025Nov 10, 2025 · Before open−2.2%
Q2 2025Aug 11, 2025 · After close−2.5%
Q1 2025May 15, 2025 · After close−2.8%
Q4 2024Mar 27, 2025−0.7%
Q3 2024Nov 20, 2024 · After close−3.2%
Q2 2024Aug 28, 2024

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck37 slidesNov 4, 2026
Investor Presentation (August 2026)Investor deck31 slidesAugust 2026
ENDO 2026Conference14 slidesJun 13, 2026
Investor Presentation (April 2026)Investor deck41 slidesApr 13, 2026
Technical Presentation (March 2026)Technical28 slidesMar 2, 2026
J.P. Morgan Healthcare Conference 2026Conference30 slidesJan 12, 2026
Investor Presentation (September 2025)Investor deck30 slidesSep 3, 2025
TD Cowen 45th Annual Health Care Conference 2025Conference27 slidesMar 3, 2025
J.P. Morgan Healthcare Conference 2025Conference26 slidesJan 13, 2025

Open Decks

IPO

Priced at US$18.00 a share on Oct 24, 2024.

Price
US$18.00 a share
Shares offered
16,000,000 shares of common stock
Offering size
US$288 million
Underwriters' option
Up to 2,400,000 more shares
Underwriters
J.P. Morgan, TD Cowen, Cantor, Wells Fargo Securities · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceAug 2, 2024
Filed publiclyOct 2, 2024
Amended twiceNewest Oct 24, 2024
Shares registered with an exchangeOct 22, 2024
Declared effective by the SECOct 24, 2024
Final prospectus, with the priceOct 25, 2024

Open IPO · From the cover of the final prospectus (424B4) filed Oct 25, 2024

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022
Revenue46.0M1.07M151.0K0
Cost of revenue1.60M
Gross profit46.0M1.07M151.0K
Research and development97.6M65.3M36.0M22.0M
Selling, general and administrative29.2M16.6M9.72M5.92M
Operating income-68.3M-80.8M2.08M-28.0M
Depreciation and amortization1.60M1.40M800.0K577.0K
EBITDA-66.7M-79.4M2.88M-27.4M
Income before tax-48.9M-72.3M-48.9M-27.7M
Income tax12.0K-498.0K691.0K
Net income-48.9M-71.8M4.18M-27.7M
Earnings per share, basic-1.10-7.260.29-1.42
Earnings per share, diluted-1.10-7.260.29

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents120.7M238.2M88.5M30.6M
Short-term investments270.4M112.7M0
Receivables10.4M171.0K151.0K0
Current assets411.0M356.8M112.7M31.9M
Property, plant and equipment4.43M5.09M4.67M
Total assets596.2M456.6M130.9M36.1M
Accounts payable10.3M3.20M2.64M3.07M
Current liabilities86.9M12.8M6.91M5.54M
Total debt23.6M25.5M12.6M710.0K
Total liabilities214.3M36.5M20.0M80.3M
Shareholders' equity381.9M420.0M-38.4M-44.2M
Shares outstanding44.8M44.4M3.17M19.5M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations110.2M-67.5M-38.7M-23.3M
Capital spending-518.0K-2.10M-2.88M-1.29M
Free cash flow109.7M-69.6M-41.6M-24.6M
Cash from investing-229.4M-160.6M22.1M-1.29M
Cash from financing1.69M377.8M74.5M30.1M
Share buybacks-1.00K-1.00K-1.00K
Change in cash-117.5M149.7M57.9M5.46M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
144 · Notice of proposed saleNov 16, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
144 · Notice of proposed saleNov 12, 2026Other filingsSEC
144 · Notice of proposed saleNov 12, 2026Other filingsSEC
144 · Notice of proposed saleNov 12, 2026Other filingsSEC
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
8-K · Current reportNov 9, 2026ResultsSEC
All 180 filings
FilingDateTypeFiled with
8-K · Current reportNov 4, 2026Current reportSEC
4 · Change in ownershipOct 19, 2026Insider tradeSEC
144 · Notice of proposed saleOct 1, 2026Other filingsSEC
144 · Notice of proposed saleOct 1, 2026Other filingsSEC
4 · Change in ownershipSep 10, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 3, 2026Insider tradeSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
8-K · Current reportAug 25, 2026Current reportSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
4 · Change in ownershipAug 13, 2026Insider tradeSEC
144 · Notice of proposed saleAug 12, 2026Other filingsSEC
144 · Notice of proposed saleAug 12, 2026Other filingsSEC
144 · Notice of proposed saleAug 12, 2026Other filingsSEC
144 · Notice of proposed saleAug 11, 2026Other filingsSEC
10-Q · Quarterly reportAug 10, 2026Quarterly reportSEC
8-K · Current reportAug 10, 2026ResultsSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
144 · Notice of proposed saleJul 15, 2026Other filingsSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
8-K · Current reportJun 30, 2026Meeting outcomeSEC
144 · Notice of proposed saleJun 26, 2026Other filingsSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
144 · Notice of proposed saleJun 22, 2026Other filingsSEC
144 · Notice of proposed saleJun 22, 2026Other filingsSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
144 · Notice of proposed saleJun 12, 2026Other filingsSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipMay 28, 2026Insider tradeSEC
144 · Notice of proposed saleMay 26, 2026Other filingsSEC
10-Q · Quarterly reportMay 11, 2026Quarterly reportSEC
8-K · Current reportMay 11, 2026ResultsSEC
ARS · Annual report to shareholdersApr 30, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 30, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 30, 2026Meeting noticeSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
8-K · Current reportApr 13, 2026Current reportSEC
S-3ASR · Registration statementMar 10, 2026Offer documentSEC
S-8 · Registration statement for employee plansMar 9, 2026Offer documentSEC
10-K · Annual reportMar 9, 2026Annual reportSEC
8-K · Current reportMar 9, 2026ResultsSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
8-K · Current reportMar 2, 2026Current reportSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 15, 2026Insider tradeSEC
8-K · Current reportJan 12, 2026Current reportSEC
8-K · Current reportJan 8, 2026Current reportSEC
4 · Change in ownershipNov 13, 2025Insider tradeSEC
144 · Notice of proposed saleNov 10, 2025Other filingsSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
8-K · Current reportNov 10, 2025ResultsSEC
4 · Change in ownershipSep 29, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 29, 2025Insider tradeSEC
8-K · Current reportSep 29, 2025Management or board changeSEC
8-K · Current reportSep 3, 2025Current reportSEC
8-K · Current reportAug 21, 2025Current reportSEC
4 · Change in ownershipAug 19, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
10-Q · Quarterly reportAug 11, 2025Quarterly reportSEC
8-K · Current reportAug 11, 2025ResultsSEC
8-K · Current reportAug 4, 2025Management or board changeSEC
8-K · Current reportJul 2, 2025Current reportSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
8-K · Current reportJun 18, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJun 10, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
8-K · Current reportMay 15, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
8-K · Current reportMay 14, 2025Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 9, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
4 · Change in ownershipApr 4, 2025Insider tradeSEC
S-8 · Registration statement for employee plansMar 27, 2025Offer documentSEC
10-K · Annual reportMar 27, 2025Annual reportSEC
8-K · Current reportMar 27, 2025ResultsSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 6, 2025Insider tradeSEC
8-K · Current reportMar 3, 2025Current reportSEC
4 · Change in ownershipFeb 27, 2025Insider tradeSEC
4 · Change in ownershipFeb 27, 2025Insider tradeSEC
4 · Change in ownershipFeb 26, 2025Insider tradeSEC
4 · Change in ownershipFeb 24, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
8-K · Current reportFeb 18, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 13, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
8-K · Current reportJan 13, 2025Current reportSEC
3 · Initial statement of ownershipJan 7, 2025Insider tradeSEC
8-K · Current reportJan 6, 2025Management or board changeSEC
10-Q · Quarterly reportNov 20, 2024Quarterly reportSEC
8-K · Current reportNov 20, 2024ResultsSEC
SC 13D · Big-stake noticeNov 4, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 4, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 1, 2024Big-stake noticeSEC
4 · Change in ownershipOct 30, 2024Insider tradeSEC
4 · Change in ownershipOct 28, 2024Insider tradeSEC
8-K · Current reportOct 28, 2024Current reportSEC
S-8 · Registration statement for employee plansOct 25, 2024Offer documentSEC
424B4 · ProspectusOct 25, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 25, 2024Other filingsSEC
3 · Initial statement of ownershipOct 24, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 24, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 24, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 24, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 24, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 24, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 24, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 24, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 24, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 24, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 24, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 24, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 24, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 24, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 24, 2024Insider tradeSEC
S-1MEF · Registration of more shares for the same offeringOct 24, 2024Offer documentSEC
CERT · Exchange's certificate of listingOct 24, 2024Other filingsSEC
S-1/A · Registration statement, amendedOct 24, 2024Offer documentSEC
8-A12B · Registration of shares for listing on an exchangeOct 22, 2024Other filingsSEC
CORRESP · Letter to the SECOct 22, 2024Other filingsSEC
CORRESP · Letter to the SECOct 22, 2024Other filingsSEC
S-1/A · Registration statement, amendedOct 21, 2024Offer documentSEC
CORRESP · Letter to the SECOct 15, 2024Other filingsSEC
CORRESP · Letter to the SECOct 2, 2024Other filingsSEC
S-1 · Registration statementOct 2, 2024Offer documentSEC
UPLOAD · Letter from the SECSep 24, 2024Other filingsSEC
DRSLTR · Letter to the SEC with a draftSep 11, 2024Other filingsSEC
DRS/A · Draft registration statement, amendedSep 11, 2024Offer documentSEC
UPLOAD · Letter from the SECSep 5, 2024Other filingsSEC
DRS · Draft registration statementAug 2, 2024Offer documentSEC
DJul 13, 2023Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Septerna, Inc.’s releases · as of Nov 4, 2026

Common shares
47,549,223
Fully diluted
47,549,223

Fully diluted

LineSharesAs of
Common shares47,549,223Nov 4, 2026

Share count over time

CountShares
Nov 4, 202647,549,223

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Trv Gp V, LLC6.07MUS$237MSep 30, 2026
Ra Capital Management, L.P.5.5MUS$215MSep 30, 2026
Driehaus Capital Management LLC4.27MUS$167MSep 30, 2026
Trv Gp VI, LLC4.21MUS$165MSep 30, 2026
Samsara Biocapital, LLC3.07MUS$120MSep 30, 2026
Goldman Sachs3.02MUS$118MSep 30, 2026
BlackRock2.07MUS$81.2MSep 30, 2026
Vanguard1.81MUS$70.9MSep 30, 2026
Siren, L.L.C.1.7MUS$66.5MSep 30, 2026
Janus Henderson1.61MUS$63.1MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Primecap Management Co1.35MUS$53MSep 30, 2026
Avoro Capital Advisors LLC1.3MUS$50.9MSep 30, 2026
First Light Asset Management, LLC1.16MUS$45.6MSep 30, 2026
ADAR1 Capital Management, LLC974KUS$38.1MSep 30, 2026
Fidelity866KUS$33.9MSep 30, 2026
State Street798KUS$31.2MSep 30, 2026
Geode Capital687KUS$26.9MSep 30, 2026
Loomis Sayles & Co L P647KUS$25.3MSep 30, 2026
Perceptive Advisors LLC567KUS$22.2MSep 30, 2026
Casdin Capital, LLC553KUS$21.6MSep 30, 2026
Catalio Capital Management, LP454KUS$17.8MSep 30, 2026
Algert Global LLC451KUS$17.7MSep 30, 2026
Soleus Capital Management, L.P.330KUS$12.9MSep 30, 2026
Braidwell LP328KUS$12.8MSep 30, 2026
Balyasny Asset Management L.P.323KUS$12.6MSep 30, 2026
D. E. Shaw & Co., Inc.233KUS$9.13MSep 30, 2026
Universal- Beteiligungs- und Servicegesellschaft mbH224KUS$8.75MSep 30, 2026
Nuveen210KUS$8.2MSep 30, 2026
Schwab209KUS$8.17MSep 30, 2026
Morgan Stanley207KUS$8.1MSep 30, 2026
Northern Trust202KUS$7.91MSep 30, 2026
Adage Capital Partners Gp, L.L.C.199KUS$7.79MSep 30, 2026
Kalehua Capital Management LLC195KUS$7.61MSep 30, 2026
Qube Research & Technologies Ltd163KUS$6.37MSep 30, 2026
UBS158KUS$6.19MSep 30, 2026
Ameriprise152KUS$5.95MSep 30, 2026
Longaeva Partners L.P.142KUS$5.57MSep 30, 2026
Arrowstreet Capital, Limited Partnership132KUS$5.15MSep 30, 2026
Two Sigma113KUS$4.41MSep 30, 2026
Dimensional107KUS$4.2MSep 30, 2026
Neuberger Berman Group LLC105KUS$4.1MSep 30, 2026
Ikarian Capital, LLC100KUS$3.91MSep 30, 2026
XTX Topco Ltd93,034US$3.64MSep 30, 2026
Federated Hermes, Inc.92,413US$3.62MSep 30, 2026
JPMorgan85,489US$3.35MSep 30, 2026
American Century79,358US$3.11MSep 30, 2026
Informed Momentum Co LLC67,579US$2.64MSep 30, 2026
Checkpoint Capital L.P.64,000US$2.5MSep 30, 2026
Bank of America63,781US$2.5MSep 30, 2026
Jacobs Levy Equity Management, Inc63,271US$2.48MSep 30, 2026

This page holds 50 of 166 holders. Open Shareholders

Funds

HolderSharesValueAs of
Vanguard Total Stock Market Index Fund928KUS$31.1MJun 30, 2026
PRIMECAP Odyssey Aggressive Growth Fund825KUS$28.4MJul 31, 2026
iShares Russell 2000 ETF579KUS$19.4MJun 30, 2026
Driehaus Small Cap Growth Fund418KUS$14MJun 30, 2026
Loomis Sayles Small Cap Growth Fund339KUS$11.3MJun 30, 2026
Vanguard Extended Market Index Fund262KUS$8.76MJun 30, 2026
Fidelity Small Cap Index Fund242KUS$8.35MJul 31, 2026
iShares Biotechnology ETF193KUS$6.45MJun 30, 2026
Driehaus Micro Cap Growth Fund158KUS$5.3MJun 30, 2026
iShares Russell 2000 Growth ETF139KUS$4.65MJun 30, 2026
Show 50 holders
HolderSharesValueAs of
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF127KUS$4.24MJun 30, 2026
Fidelity Extended Market Index Fund117KUS$3.53MMay 31, 2026
Column Small Cap Select Fund111KUS$3.35MMay 31, 2026
Vanguard Russell 2000 Index Fund110KUS$3.32MMay 31, 2026
Schwab U.S. Small-Cap ETF108KUS$3.27MMay 31, 2026
Small Cap Equity Fund104KUS$3.5MJun 30, 2026
North Square Dynamic Small Cap Fund102KUS$3.09MMay 31, 2026
JNL Multi-Manager Small Cap Growth Fund102KUS$3.43MJun 30, 2026
AST Small-Cap Equity Portfolio101KUS$3.39MJun 30, 2026
Adara Smaller Companies Fund77,166US$2.33MMay 31, 2026
iShares Russell 2000 Value ETF65,273US$2.19MJun 30, 2026
Invesco Dorsey Wright SmallCap Momentum ETF63,077US$1.9MMay 31, 2026
Hussman Strategic Market Cycle Fund60,000US$2.01MJun 30, 2026
Fidelity SAI Small-Mid Cap Momentum Index Fund59,999US$2.07MJul 31, 2026
iShares U.S. Pharmaceuticals ETF59,605US$2MJun 30, 2026
Federated Hermes MDT Small Cap Core Fund55,289US$1.9MJul 31, 2026
Schwab Small-Cap Index Fund53,751US$1.85MJul 31, 2026
Loomis Sayles Small Cap Growth Portfolio53,388US$1.79MJun 30, 2026
Avantis U.S. Small Cap Equity ETF51,545US$1.56MMay 31, 2026
Vanguard U.S. Momentum Factor ETF48,858US$1.48MMay 31, 2026
Fidelity Total Market Index Fund42,435US$1.28MMay 31, 2026
Master Small Cap Index Series41,369US$1.39MJun 30, 2026
Fidelity Series Total Market Index Fund34,866US$1.05MMay 31, 2026
Vanguard Health Care Index Fund33,204US$1MMay 31, 2026
Fidelity Nasdaq Composite Index Fund30,358US$917KMay 31, 2026
JPMorgan Small Cap Value Fund29,897US$1MJun 30, 2026
iShares Core S&P Total U.S. Stock Market ETF29,513US$988KJun 30, 2026
Nuveen Small Cap Blend Index Fund29,302US$1.01MJul 31, 2026
Destinations Small-Mid Cap Equity Fund26,611US$804KMay 31, 2026
Dimensional U.S. Small Cap ETF24,347US$839KJul 31, 2026
EQ/2000 Managed Volatility Portfolio24,070US$806KJun 30, 2026
EQ/Small Company Index Portfolio19,700US$660KJun 30, 2026
Select Biotechnology Portfolio19,400US$586KMay 31, 2026
JPMorgan Diversified Return U.S. Small Cap Equity ETF18,656US$643KJul 31, 2026
Fidelity Nasdaq Composite Index ETF17,360US$524KMay 31, 2026
Vanguard Russell 2000 Value Index Fund16,907US$511KMay 31, 2026
Loomis Sayles Small Cap Core Portfolio16,804US$563KJun 30, 2026
LVIP Franklin Templeton Multi-Factor SMID Cap Equity Fund16,200US$543KJun 30, 2026
Vanguard Balanced Index Fund15,893US$532KJun 30, 2026
LVIP State Street Small-Cap Index Fund15,800US$529KJun 30, 2026

This page holds 50 of 174 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Labrucherie Gil M
Officer: Chief Financial Officer
Sale15,815USD 41.48US$656KNov 16, 2026
Labrucherie Gil M
Officer: Chief Financial Officer
Sale3,485USD 41.99US$146KNov 16, 2026
Labrucherie Gil M
Officer: Chief Financial Officer
Sale700USD 43.00US$30,100Nov 16, 2026
Finer Jeffrey
Director, Officer: Chief Executive Officer
Sale5,600USD 42.09US$236KNov 12, 2026
Finer Jeffrey
Director, Officer: Chief Executive Officer
Sale5,300USD 43.10US$228KNov 12, 2026
Finer Jeffrey
Director, Officer: Chief Executive Officer
Sale2,800USD 44.23US$124KNov 12, 2026
Finer Jeffrey
Director, Officer: Chief Executive Officer
Sale2,823USD 45.28US$128KNov 12, 2026
Finer Jeffrey
Director, Officer: Chief Executive Officer
Sale1,977USD 46.16US$91,264Nov 12, 2026
Ezekowitz Alan
Director
Sale6,939USD 46.01US$319KNov 11, 2026
Ezekowitz Alan
Director
Sale13,201USD 47.01US$621KNov 11, 2026
All 38 trades
TradeTradeSharesPriceValueDate
Ezekowitz Alan
Director
Sale22,865USD 47.78US$1.09MNov 11, 2026
Ezekowitz Alan
Director
Sale31,572USD 48.70US$1.54MNov 11, 2026
Ezekowitz Alan
Director
Sale4,175USD 49.65US$207KNov 11, 2026
Ezekowitz Alan
Director
Sale2,013USD 50.90US$102KNov 11, 2026
Ezekowitz Alan
Director
Sale1,055USD 51.90US$54,755Nov 11, 2026
Bhatt Elizabeth
Officer: President and COO
Sale1,094USD 36.87US$40,337Oct 15, 2026
Bhatt Elizabeth
Officer: President and COO
Sale2,906USD 37.61US$109KOct 15, 2026
Long Daniel D.
Officer: SVP, Drug Discovery
Sale3,333USD 37.83US$126KSep 1, 2026
Third Rock Ventures GP VI, L.P.
10% owner
Sale147,059USD 50.27US$7.39MAug 12, 2026
Third Rock Ventures GP VI, L.P.
10% owner
Sale141USD 51.08US$7,202Aug 12, 2026
Shah Rajeev M.
Director, 10% owner
Sale746,500USD 42.50US$31.7MAug 12, 2026
Bhatt Elizabeth
Officer: President and COO
Sale25,000USD 44.00US$1.1MAug 11, 2026
Long Daniel D.
Officer: SVP, Drug Discovery
Sale1,000USD 33.98US$33,980Aug 3, 2026
Long Daniel D.
Officer: SVP, Drug Discovery
Sale2,334USD 34.68US$80,943Aug 3, 2026
Bhatt Elizabeth
Officer: President and COO
Sale4,000USD 33.99US$136KJul 15, 2026
Long Daniel D.
Officer: SVP, Drug Discovery
Sale2,100USD 34.10US$71,610Jul 1, 2026
Long Daniel D.
Officer: SVP, Drug Discovery
Sale1,233USD 34.81US$42,921Jul 1, 2026
Shaikhly Samira
Officer: Chief People Officer
Sale2,178USD 35.18US$76,622Jun 29, 2026
Long Daniel D.
Officer: SVP, Drug Discovery
Sale8,000USD 35.10US$281KJun 22, 2026
Long Daniel D.
Officer: SVP, Drug Discovery
Sale7,000USD 35.97US$252KJun 22, 2026
Shaikhly Samira
Officer: Chief People Officer
Sale6,250USD 35.08US$219KJun 12, 2026
Shaikhly Samira
Officer: Chief People Officer
Sale1,700USD 27.78US$47,226Jun 1, 2026
Shaikhly Samira
Officer: Chief People Officer
Sale1,346USD 28.79US$38,751Jun 1, 2026
Shaikhly Samira
Officer: Chief People Officer
Sale2,889USD 29.66US$85,688Jun 1, 2026
Shaikhly Samira
Officer: Chief People Officer
Sale11,798USD 30.06US$355KMay 26, 2026
Bhatt Elizabeth
Officer: President and COO
Sale2,573USD 23.76US$61,134Apr 15, 2026
Bhatt Elizabeth
Officer: President and COO
Sale1,101USD 25.24US$27,789Apr 15, 2026
Bhatt Elizabeth
Officer: President and COO
Sale326USD 25.86US$8,430Apr 15, 2026

Big stakes

StakeStakeSharesDateFiling
Third Rock Ventures V, L.P.13.00%6.07MSep 30, 2026Schedule 13G
Ra Capital Management, L.P.11.80%5.53MAug 12, 2026Schedule 13D
Driehaus Capital Management LLC9.83%4.43MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Rajeev M Shah
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past)
Director · Since at least Oct 24, 2024
Rajiv Patni
Other companies: BioXcel Therapeutics, Inc. (Director · Since at least Jan 15, 2025); Quince Therapeutics, Inc. (Director · Since at least Feb 15, 2024); Reata Pharmaceuticals Inc (EVP, Chief R&D Officer · Jun 12, 2023 – Sep 26, 2023 · Past); Portola Pharmaceuticals Inc (EVP, CMO · Feb 3, 2020 – Jul 2, 2020 · Past); Adamas Pharmaceuticals Inc (Chief Medical Officer · Jun 8, 2015 – Apr 8, 2019 · Past); Ocera Therapeutics Inc (Chief Development Officer · Sep 2, 2014 – May 7, 2015 · Past)
Chief Medical Officer · Since at least Aug 24, 2026
Jeffrey Tong
Other companies: Maze Therapeutics, Inc. (Director · Jan 30, 2025 – Jan 30, 2025 · Past); Rapport Therapeutics, Inc. (Director · Jun 6, 2024 – Jun 6, 2024 · Past); Nurix Therapeutics, Inc. (Director · Jul 23, 2020 – May 6, 2021 · Past)
Chairman of the Board · Since at least Oct 24, 2024
Keith Gottesdiener
Other companies: Prime Medicine, Inc. (See Remarks, Director · Oct 19, 2022 – May 8, 2025 · Past); Rhythm Pharmaceuticals, Inc. (CEO & President, Director · Oct 4, 2017 – Mar 9, 2020 · Past); Intercept Pharmaceuticals Inc (Director · Jul 19, 2016 – Nov 8, 2023 · Past)
Director · Since at least Sep 25, 2025
Liz Bhatt
Other companies: eFFECTOR Therapeutics Inc (Director · Aug 25, 2021 – Jun 13, 2024 · Past); Applied Molecular Transport Inc (Chief Bus. & Strategy Officer · Jun 4, 2020 – Feb 15, 2022 · Past); Achaogen Inc (Chief Operating Officer · Jul 26, 2018 – Feb 21, 2019 · Past)
President and Chief Operating Officer · Since at least Oct 24, 2024
Alan Ezekowitz
Other companies: Organon & Co. (Director · Since at least Jun 2, 2021); Fulcrum Therapeutics, Inc. (Director · Since at least Jul 17, 2019)
Director · Since at least Oct 24, 2024
Gil Labrucherie
Other companies: Rezolute, Inc. (Director · Since at least Jan 23, 2024); Acelyrin, Inc. (CFO and CBO · Oct 4, 2023 – Aug 31, 2024 · Past)
Chief Financial Officer · Since at least Jan 6, 2025
Jae B Kim
Other companies: Design Therapeutics, Inc. (Chief Medical Officer · Mar 13, 2024 – Mar 13, 2024 · Past); Avidity Biosciences, Inc (Chief Medical Officer · Jul 27, 2020 – Feb 2, 2021 · Past)
Chief Medical Officer · Since at least Oct 24, 2024
Bernard Coulie
Other companies: Pliant Therapeutics, Inc. (Director · Since at least Jun 2, 2020)
Director · Since at least Oct 24, 2024
Jake Simson
Other companies: Janux Therapeutics, Inc. (Director · Since at least Jun 11, 2026)
Director · Since at least Nov 5, 2026
All 18 people
PersonSeat
Shalini Sharp
Other companies: Organon & Co. (Director · Since at least Nov 5, 2026)
Director · Since at least Nov 5, 2026
Abraham BassanDirector · Since at least Nov 5, 2026
Daniel LongSenior Vice President, Drug Discovery · Since at least Oct 24, 2024
Jeffrey FinerChief Executive Officer, Director · Since at least Apr 2, 2025
Mark A. WilsonChief Legal Officer · Since at least Jan 8, 2026
Ran XiaoInterim CFO · Oct 24, 2024 – Oct 24, 2024 · Past
Samira ShaikhlyChief People Officer · Since at least Jun 30, 2026
Uwe KleinSenior Vice President, Biological Sciences · Since at least Aug 7, 2025

Open People

Log in to ask 6ix AI your own questions about Septerna, Inc.